- Home
- WHWK vs MNOV Comparison
WHWK vs MNOV Comparison
Compare WHWK & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHWK
- MNOV
- Stock Information
- Founded
- WHWK 2007
- MNOV 2000
- Country
- WHWK United States
- MNOV United States
- Employees
- WHWK N/A
- MNOV N/A
- Industry
- WHWK Biotechnology: Pharmaceutical Preparations
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- WHWK Health Care
- MNOV Health Care
- Exchange
- WHWK Nasdaq
- MNOV Nasdaq
- Market Cap
- WHWK 82.4M
- MNOV 68.2M
- IPO Year
- WHWK N/A
- MNOV 2005
- Fundamental
- Price
- WHWK $1.78
- MNOV $1.35
- Analyst Decision
- WHWK
- MNOV Strong Buy
- Analyst Count
- WHWK 0
- MNOV 2
- Target Price
- WHWK N/A
- MNOV $7.00
- AVG Volume (30 Days)
- WHWK 105.5K
- MNOV 49.3K
- Earning Date
- WHWK 08-15-2025
- MNOV 08-11-2025
- Dividend Yield
- WHWK N/A
- MNOV N/A
- EPS Growth
- WHWK N/A
- MNOV N/A
- EPS
- WHWK 0.91
- MNOV N/A
- Revenue
- WHWK $27,775,000.00
- MNOV N/A
- Revenue This Year
- WHWK $49.83
- MNOV N/A
- Revenue Next Year
- WHWK N/A
- MNOV N/A
- P/E Ratio
- WHWK $1.95
- MNOV N/A
- Revenue Growth
- WHWK 16.51
- MNOV N/A
- 52 Week Low
- WHWK $1.21
- MNOV $1.12
- 52 Week High
- WHWK $3.81
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- WHWK N/A
- MNOV 52.38
- Support Level
- WHWK N/A
- MNOV $1.32
- Resistance Level
- WHWK N/A
- MNOV $1.50
- Average True Range (ATR)
- WHWK 0.00
- MNOV 0.07
- MACD
- WHWK 0.00
- MNOV 0.01
- Stochastic Oscillator
- WHWK 0.00
- MNOV 46.43
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.